AstraZeneca seeks UK approval for baxdrostat, but the trial was tiny

A once-daily pill called baxdrostat lowered blood pressure to normal levels in a small trial of patients whose hypertension was attributed to an overactive hormone, according to a report published on 7 November 2026. Improvements were reportedly still evident two years after patients stopped taking the pills. Baxdrostat is not yet available on the NHS, and manufacturer AstraZeneca is seeking UK approval.

The report links the hormone-driven mechanism to 800,000 cases in Britain. For those patients, a course of tablets could replace lifelong blood pressure management or surgery.

But the evidence is a small trial in a specific subtype. The trial size, whether it was randomised and controlled, the number of patients in each arm, and whether the results have been peer-reviewed or published in a journal are not stated in the report. The two-year remission signal has not been independently verified.

For most people with high blood pressure, the practical picture is unchanged. The condition remains managed with existing drugs, lifestyle changes, and in some cases surgery. Separate real-world evidence on intensive blood pressure targets — below 130/80 mmHg — associates tighter control with lower risk of hypertension-related complications and all-cause mortality, without a significant increase in serious adverse events. That is a target-trial emulation, not a randomised trial, so it shows association rather than causation, but it supports what clinicians already do: get blood pressure down and keep it down.

The near-term question is not whether baxdrostat is a cure. It is whether the remission effect replicates in a larger, controlled trial, and whether UK regulators grant approval. Until then, the drug is not available on the NHS, and the 800,000 figure describes a mechanism, not a treated population.